Louisiana State Employees Retirement System acquired a new position in shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 3,900 shares of the specialty pharmaceutical company’s stock, valued at approximately $251,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ANIP. BNP Paribas Arbitrage SA boosted its position in shares of ANI Pharmaceuticals by 44.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock worth $101,000 after purchasing an additional 664 shares in the last quarter. SG Americas Securities LLC acquired a new stake in ANI Pharmaceuticals during the 3rd quarter worth about $197,000. Stevens Capital Management LP acquired a new stake in ANI Pharmaceuticals during the 2nd quarter worth about $207,000. Dynamic Technology Lab Private Ltd acquired a new stake in ANI Pharmaceuticals during the 2nd quarter worth about $210,000. Finally, Violich Capital Management Inc. acquired a new stake in ANI Pharmaceuticals during the 3rd quarter worth about $217,000. Institutional investors own 53.51% of the company’s stock.
ANI Pharmaceuticals Inc (ANIP) opened at $58.41 on Tuesday. The company has a debt-to-equity ratio of 0.83, a current ratio of 3.45 and a quick ratio of 2.39. ANI Pharmaceuticals Inc has a twelve month low of $42.23 and a twelve month high of $74.70. The company has a market capitalization of $680.07, a P/E ratio of 92.71 and a beta of 2.79.
ANIP has been the subject of several analyst reports. Canaccord Genuity reissued a “buy” rating and issued a $66.00 price objective (up previously from $60.00) on shares of ANI Pharmaceuticals in a report on Monday, October 16th. ValuEngine upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 4th. Zacks Investment Research upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research note on Tuesday, November 7th. TheStreet upgraded ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, November 16th. Finally, BidaskClub lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 21st. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. ANI Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $71.00.
WARNING: “Louisiana State Employees Retirement System Takes Position in ANI Pharmaceuticals Inc (NASDAQ:ANIP)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/13/louisiana-state-employees-retirement-system-purchases-shares-of-3900-ani-pharmaceuticals-inc-anip.html.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.